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Abstract 
The synthesis of heparin oligosaccharide fragments by autocondensation of suitably protected D-
glucosamine α1→4 L-iduronic acid disaccharide constructs containing both glycosyl- donor and 
glycosyl- acceptor functionalities has been explored. Trichloroacetimidate and n-pentenyl groups 
have been investigated for anomeric activation. The generation of building blocks equipped with 
a trichloroacetimidate function is seriously hampered by the presence of the free- OH glycosyl-
acceptor group on the same molecule, which favors an intramolecular transesterification 
reaction. Using an n-pentenyl leaving group, the glycosylation promoter competes as a 
nucleophile with the OH glycosyl acceptor in the autocondensation process, giving rise to fast 
termination of the chain reaction, a low yield, and low degree of polymerization. It is concluded 
that, in this area, polycondensation can hardly compete with elaborate stepwise approaches as a 
result of the intrinsic low reactivity—both as a glycosyl donor and as glycosyl acceptor—of the 
D-glucosamine α1→4 L-iduronic acid building blocks. 
 
Keywords: Heparin oligosaccharides, synthesis, polycondensation, trichloroacetimidate, n-
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Introduction 
 
As part of a program on the molecular basis of the activation of fibroblast growth factors (FGFs) 
by glycosaminoglycans (GAGs) we have developed a modular approach for a completely 
stereoselective block synthesis of oligosaccharides containing the repeating unit (D-glucosamine 
α1→4 L-iduronate) of the major sequence of heparin.1 This approach, which has been extended 
successfully to solid-phase synthesis using an acceptor-bound strategy,2 has allowed the 
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preparation of several hexa- and octa-saccharides with different charge distributions and 
orientations 3 which have been used for structure-activity studies.4 FGFs 5 constitute a family of 
polypeptides belonging to the class of heparin- binding proteins.6 These heparin- binding 
proteins 6 are involved in important cellular functions and their biological activities are tightly 
regulated by heparan sulfate GAGs.7 Because of the intrinsic heterogeneity of GAGs,7 the 
synthesis of heparin oligosaccharide fragments with defined size, sequence, and charge 
distribution is essential for understanding the GAG–protein molecular recognition phenomena in 
living systems. The size and the sequence of the oligosaccharide fragment, and the distribution 
and orientation of sulfate groups along the oligosaccharide chain, are thought to play a key role 
in these recognition events.6 
Effective as our reported block synthesis may be, the preparation of heparin fragments for 
interaction studies requires the development of new methods to speed up and simplify the 
process. In this paper we explore the scope and the limitations of a polycondensation reaction of 
conveniently protected building blocks to construct the oligosaccharide skeleton in a single 
polymerization step. 
 
 
Results and Discussion 
 
Our block synthesis of heparin oligosaccharide fragments is based on the stereoselective 
assembly of disaccharide building blocks with protecting group patterns designed to achieve a 
defined distribution of sulfate groups in the final product.1–3 We thought that a polycondensation 
reaction of a properly selected disaccharide building block as the repeating unit would represent 
an attractive alternative to the stepwise synthesis for the preparation of regular sequences. The 
synthesis of polysaccharides using a controlled chemical polymerization has been attempted 
previously with success in a few cases,8 and the enzymatic polymerization of a disaccharide 
building block has been used to synthesize a fragment of the GAG hyaluronan.9 Cationic ring-
opening- polymerization has been reported from 1,2-ortho-esters 10 and 1,6-anhydrohexoses,8c 
and polycondensation reactions have been described from 1,2-cyanoethylene derivatives.8a We 
envisaged the possibility of generating homogeneously protected heparin oligosaccharide 
fragments by autocondensation of a suitably protected disaccharide repeating unit as indicated in 
Chart 1.  
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Chart 1. Principle of proposed autocondensation reaction. 
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For their proven efficiency in our stepwise synthesis of heparin oligosaccharides 1–3 we first 
used trichloroacetimidates as leaving groups. Thus, the preparation of a bifunctional 
trichloroacetimidate carrying both glycosyl-donor and glycosyl-acceptor functionalities was 
attempted from disaccharide 11,3a which is currently used in our stepwise syntheses. Compound 1 
was converted into 2 following a well established sequence,1,3a and 2 was desilylated 11 to give 
the diol 3 (Scheme 1). 
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Scheme 1. Reagents and conditions: (i) EtSH, p-TsOH, CH2Cl2; (ii) BzCN, Et3N, CH3CN, 92%; 
(iii) HF:pyr, THF, 4ºC, 94%. 
 
Attempted selective installation of the trichloroacetimidate group at the anomeric position of 
diol 3 by treatment with a slight excess of trichloroacetonitrile in the presence of K2CO3 12 
afforded lactone 4 as the main product (Scheme 2). When this reaction was performed with 
excess of reagent a mixture of 4 and the trichloroacetimidate 5 was formed. The unexpected 
formation of 4 by intramolecular transesterification of the methyl ester group with the free 
anomeric hydroxyl group appears to be a consequence of the presence of the free 4’-OH in 3, 
since this reaction has never before been observed in trichloroacetimidate formation in this 
series. In this reaction, which involves a conformational inversion of the L-iduronic acid 
pyranoid ring followed by the base- promoted transesterification of the methyl ester, the 4’-OH 
may be involved in the activation of the ester function through a hydrogen bridge. In any case, 
these results demonstrated that trichloroacetimidate anomeric activation is not suitable for 
straightforward generation of the disaccharide repeating unit and other activation methods had to 
be investigated. 
We then turned our attention to n-pentenyl activation as pentenyl glycosides 13 had been 
reported to be effective glycosylating agents in the coupling of L-iduronic acid derivatives to the 
4-OH group of D-glucosamine units.14 However, the installation of the n-pentenyl group at the 
anomeric position of a L-iduronic acid derivative has proven to be feasible only after previously 
activating that position as a bromide or a trichloroacetimidate.15 Therefore, the known 
trichloroacetimidate 6 3c was reacted 16 with excess pent-4-en-1-ol to give the n-pentenyl 
glycoside 7 in 62% yield (Scheme 3).  
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Scheme 2. (i) K2CO3, Cl3CN, CH2Cl2. 
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Scheme 3. (i) 4-penten-1-ol, TMSOTf, CH2Cl2, 47%. 
 
Compound 7 was transformed into the bifunctional building block 9 by trans-acetalation of 
the benzylidene acetal 17 to give diol 8 followed by selective benzoylation 18 of the primary 
hydroxyl group in 8 (Scheme 4). Compound 9, endowed with a leaving group at the anomeric 
position and a free hydroxyl group at the 4’- position, and having a protecting group pattern 
encoding the negative charge distribution of the regular region of heparin was then submitted to 
autocondensation conditions. 
 
O
O
OBn
Bz
MeO2C
O
BzO
HO
BnO
N3
O
O
O
OBn
OBz
MeO2C
O
O
O
BnO
N3
Ph
O
O
O
OBn
Bz
MeO2C
O
HO
HO
BnO
N3
O
7
8
9i
ii
 
 
Scheme 4. (i) EtSH, BF3OEt2, CH2Cl2, 72%; (ii) BzCN, Et3N, CH2Cl2, 92%. 
 
It was expected that the reaction of 9 with a promoter (equimolecular NIS and catalytic 
Et3SiOTf 19) would generate a glycosyl carbonium ion 13b that may react with any nucleophile 
present in the reaction mixture. Under strictly anhydrous conditions, the carbonium ion would 
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react with the 4’-OH group of a second disaccharide building block to give a tetrasaccharide 
species that itself carries donor–acceptor functionalities. This tetrasaccharide species may give 
rise to a hexasaccharide or an octasaccharide depending on the concentration of each species, the 
nucleophilicity of the acceptor OH group, and the concentration of the promoter. 
Compound 9 was dissolved in dichloromethane under strictly anhydrous conditions and 
treated with solid NIS and a catalytic amount of Et3SiOTf 19 at 0º C. The reaction was monitored 
by TLC. When no further evolution was observed the reaction mixture was acetylated by 
treatment with acetic anhydride and pyridine in the presence of DMAP.20 It was then submitted 
to extensive TLC fractionation and compounds 10–13 could be isolated and characterized 
(Scheme 5). The presence of the N-succinyl derivatives 10 and 11 indicated that under the 
reaction conditions the succinimide nucleophile competes strongly with the 4’-OH group for the 
NIS–Et3SiOTf- generated glycosyl carbonium ion, and this leads to a rapid end of the chain 
reaction. The formation of N-succinyl glycosides has been reported as a side reaction in the 
glycosylation of glycosyl acceptors of low reactivity with thioglycosides.21 The fact that N-
succinyl glycosides are formed at the disaccharide level (compound 11), and the absence of 
higher oligomers in the reaction mixture, are clear indications of the limited efficiency of this 
offset for autocondensation reactions. 
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Scheme 5. (i) Et3SiOTf, NIS, CH2Cl2; (ii) Ac2O, pyridine. 
 
When the reaction was carried out under TMSOTf catalysis with 1.1 eq. of NIS in 
dichloromethane, a fraction containing tetra- and hexa-saccharide was formed in 11% yield 
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(calculated from (NMR). However, higher oligomers from subsequent glycosylation cycles could 
never be observed. 
 
 
Conclusions 
 
From this exploratory study it can be concluded that the glucosamine α1→4 L-iduronate building 
block is not a suitable candidate for self-condensation, because it has low reactivity both as a 
glycosyl donor and as a glycosyl acceptor. In fact, uronic acids had a poor performance under the 
classical tritylcyanoethylidene polycondensation conditions.22 The use of a trichloroacetimidate 
function for anomeric activation seems to be precluded since the presence of a free 4’-OH in the 
disaccharide building block leads to intramolecular transesterification of the methyl ester with 
the free anomeric hydroxyl group during the attempted selective installation of the 
trichloroacetimidate group in the anomeric position. The use of more stable leaving groups, such 
as the n-pentenyl group, for anomeric activation allows protecting-group manipulation, but 
suffers from the fact that equimolecular amounts of promoter are required. Being a nucleophile 
itself, the promoter competes with the acceptor alcohol in the polycondensation process, which 
results in fast chain-reaction termination and a low yield and degree of polymerization. Since the 
preparation of the starting disaccharide building block involves a laborious process, the synthesis 
of homogeneous heparin oligosaccharide fragments by self-condensation does not seem to 
compete with the sequential assembly of disaccharide building blocks using classical 
deprotection–glycosylation strategies.  
 
 
Experimental Section 
 
General Procedures. Tetrahydrofuran, toluene, 1,4-dioxane and diethyl ether were distilled 
from sodium under nitrogen prior to use. Dichloromethane, and acetonitrile were distilled from 
calcium hydride and used immediately after distillation. DMF, pyridine and methanol were 
commercial high-grade solvents (SDS, Prolabo, France) and stored under Argon over molecular 
sieves (4Å). All reagents were purchased from Aldrich, Fluka, Lancaster, Panreac, Acros, or 
SDS. All reactions were carried out under argon in pre-dried glassware, unless otherwise stated. 
Analytical thin layer chromatography (TLC) was performed on silica gel 60 F254 pre-coated on 
aluminum plates (Merck, Darmstadt) and the compounds detected by staining with 
phosphomolybdic acid/EtOH or with anisaldehyde solution [anisaldehyde (25 ml) with sulfuric 
acid (25 ml), ethanol (450 ml) and acetic acid (1ml)] with detection by heating above 200ºC. 
Flash-column chromatography was carried out on silica gel 60 (0.2–0.5 mm, 0.2–0.063 mm or 
0.040–0.015 mm; Merck, Darmstadt) under a pressure of 0.3–0.8 bar. Preparative TLC 
purifications were carried out on Merck 20x20 cm silica-gel 60 F254-plates. Gel-permeation 
chromatography used Sephadex LH-20 and G-25 gels (medium and fine) from Pharmacia, on 
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Pharmacia columns equipped with a fraction collector. Optical rotations were determined with a 
Perkin-Elmer 341 polarimeter at 589 nm and r.t. 1H- and 13C-NMR, as all two-dimensional 
spectra were acquired on Bruker DPX-300, DRX-400 and DRX-500 spectrometers, and 
chemical shifts are given in ppm (δ) relative to tetramethylsilane as internal reference or relative 
to D2O. FAB MS were measured by the Mass Spectrometry Service, Facultad de Química, 
Seville, with a Kratos MS-80 RFA spectrometer, MALDI-TOF-MS were recorded on a Hewlett 
Packard 2030A system, usually with 2,5-dihydroxybenzoic acid (DHB-matrix). Elemental 
analysis was performed on a Leco CHNS-932 apparatus, after drying the sample over 
phosphorus pentoxide. 
 
2-Azido-6-O-benzoyl-3-O-benzyl-2-deoxy-D-glucopyranosyl-α-(1→4)-methyl (2-O-pivaloyl-
3-O-benzyl)-α/β-L-idopyranosid)-uronate (3). The 6-O-benzoylated disaccharide 3 (962 mg, 
1.06 mmol) was dissolved in THF (30 ml) and the solution split in two portions and stirred under 
argon in PE-flasks. After cooling to –20°C, excess HF pyr (2 ml/for each charge) was added via 
syringe and the reaction mixtures stirred at 4°C for two days. Et2O (30 ml each) was added for 
dilution and the crude reaction mixture neutralized with sat. NaHCO3-sol. and washed with 
brine. Concentration under reduced pressure followed by chromatography (ethyl acetate/hexane 
2:1) of the crude product afforded 3 (910 mg, 1.0 mmol, 94%) as a colorless foam. TLC 
(hexane/ethyl acetate 2:1) Rf 0.24, [α]rtD +39.68° (c 0.93, CHCl3); 1H-NMR (500 MHz, CDCl3) 
data for α-anomer δ 8.01–7.99 (d, J = 7.1 Hz, 1H; Bz), 7.71–-7.26 (m, 13H; Bz, Bn), 5.38–5.35 
(m, 1H; α-H-1), 5.03 (d, J1,2 = 3.6 Hz, 1H, H-1´), 4.88–4.75 (m, 7H; H-2, H-6a´, H-5, CH2Ph), 
4.41–4.38 (m, 1H; H-6b´), 4.15–4.12 (m, 1H, H-4), 4.11–4.07 (m, 1H, H-3), 3.95–3.93 (m, 1H, 
H-5´), 3.79 (s, 3H; COOMe), 3.73–3.71 (m, 1H, OH-1´), 3.53–3.50 (m, 1H, H-4´), 3.21 (dd, J = 
3.6 Hz, J = 10.2 Hz, 1H, H-2´), 3.08 (bs, 1H, OH-4´), 1.23 (s, 9H, t-Bu). FAB-MS m/z 785 
(M+Na+), C39H45N3O13 (763.79). Anal. Calcd. C, 61.33; H, 5.94; N, 5.50. Found C, 61.29; H, 
6.03; N, 5.63.  
2-Azido-3-O-benzyl-4,6-di-O-benzylidene-2-deoxy-D-glucopyranosyl-α-(1→4)-3-O-benzyl-
α-L-idopyranosid)-6,1-lactone (4). A solution of 3 (70 mg, 0.091 mmol) in CH2Cl2 (2 ml) under 
inert gas was cooled to 0°C and after addition of trichloroacetonitrile (11µl, 0.109 mmol) was 
treated with freshly activated K2CO3 (14 mg, 0.1mmol). The mixture was stirred overnight at r.t., 
diluted with CH2Cl2 (2 ml), filtered through a pad of Celite and concentrated in vacuo. 
Compound 4 (0.058 mmol, 42 mg, 64%) was isolated as the major product by column 
chromatography on silica gel (hexane/ethyl acetate 8:1). TLC (toluene/ethyl acetate 6:1) Rf 0.46; 
[α]rtD +50.68º (c 1.33, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.99 (d, J = 7.6 Hz, 2H; Bz), 
7.57–7.24 (m, 13H; Ph), 5.82 (d, J1,2 = 2.0 Hz, 1H; H-1), 5.12 (d, J1´,2´ = 3.8 Hz, 1H; H-1´), 5.00 
(d, Jgem = 10.6 Hz, 1H, CH2Ph), 4.93 (dd, J2,1 = 1.8 Hz, J2,3 = 7.7 Hz, 1H; H-2), 4.89 (s, 2H; 
CH2Ph), 4.80 (dd, J5´,6´ = 4.1 Hz, J6´a,6´b = 12.4 Hz, 1H; H-6´a), 4.71 (d, J5,4 = 3.75 Hz, 1H; H-5), 
4.65 (d, Jgem 10.6 Hz, 1H; CH2Ph), 4.49 (dd, J5´, 6´ = 1.8 Hz, J6´a,6´b = 12.4 Hz; H-6´b), 4.36–4.34 
(m, 1H; H-5´), 3.96–3.91 (m, 2H; H-3, H-4), 3.81 (t, J3´,4´ = J2´,3´ = 9.2 Hz; 1H, H-3´), 3.60–3.56 
(m, 1H; H-4´), 3.49 (dd, J2´,1´= 3.8 Hz, J2´,3´ = 10.2 Hz; 1H, H-2´), 2.95 (d, J4´´, OH-4´ = 2.9 Hz, 
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1H; OH-4´), 1.22 (s, 9H; t-Bu). FAB-MS m/z 754 (M+Na+), 772 (M+K+), C38H41N3O12 (731.75). 
Anal. Calcd. C, 62.37; H, 5.65; N, 5.74; Found C, 62.40; H, 5.71; N, 5.74. 
O-(Methyl 4-O-(2-azido-3-O-benzyl-6-O-benzoyl-2-deoxy-4-O-trichloracetamido-α-D-gluco-
pyranosyl)-3-O-benzyl-2-O-pivaloyl-α/β−L-idopyranosyluronate) trichloro- acetimidate (5). 
To a solution of 3 (100 mg, 0.11 mmol) in CH2Cl2 (2 ml) was added trichloracetonitrile (165 µl, 
1.65 mmol) and one drop of DBU at r.t. The reaction mixture was stirred overnight, diluted with 
CH2Cl2 (3 ml) and the solvents removed under reduced pressure. The resulting oil was purified 
on a silica-gel column (toluene/ethyl acetate, 40:1) to afford the bis-trichloroacetimidate 5 
(41 mg, 0.39 mmol) and lactone 4 (38 mg, 0.052 mmol). Data for trichloroacetimidate 5: TLC 
(hexane/ethyl acetate 3:1) Rf 0.47; [α]rtD +30.42° (c 1.69, CHCl3), 1H-NMR (500 MHz, CDCl3) δ 
8.70 (s, 1H; NH), 8.62 (s, 1H; NH), 8.03 (d, J = 7.3 Hz, 2H; Bz), 8.00–726 (m, 13H; Ph), 6.41 
(s, 1H; H-1), 5.65 (t, J4,3 = J4,5 = 9.7 Hz, 1H; H-4´), 5.18 (t, J1,2 = J2,3 = 2.6 Hz, 1H; H-2), 5.03 
(d, J1´,2´ = 3.6 Hz, 1H, H-1´), 4.94 (d, J5,4 = 2.6 Hz, 1H; H-5), 4.82 (d, Jgem = 11.4 Hz, 1H; 
CH2Ph), 4.77 (d, Jgem = 10.1 Hz, 1H; CH2Ph), 4.72 (d, Jgem = 11.4 Hz, 1H; CH2Ph), 4.62 (dd, 
J6´a,5´ = 1.5 Hz, J6´a,6´b = 12.5 Hz, 1H; H-6´a), 4.34–4.28 (m, 2H; H-5´, H-6´b), 4.25 (t, J4,5 = J4,3 
= 3.6 Hz, 1H; H-4), 4.09 (t, J3´,4´ = J3´,2´ = 9.7 Hz, 1H; H-3´), 4.04 (t, J3,4 = J3,2 = 3.4 Hz, 1H; H-
3), 3.81 (s, 3H; COOCH3), 3.51 (dd, J2´,1´ = 3.6 Hz, J2´,3´ = 10.2 Hz, 1H, H-2´), 1.28 (s, 9H; 
C(CH3)3), 13C-NMR (125 MHz, CDCl3) δ 177.44, 166.07, 161.45, 137.09, 133.16, 133.09, 
128.85, 129.79, 129.71, 128.61, 128.58, 128.49, 128.45, 128.43, 128.30, 128.21, 128.12, 127.98, 
127.81, 127.78, 127.73, 127.67, 99.15, 85.61, 93.57, 78.10, 77.96, 75.23, 75.06, 74.49, 74.11, 
73.76, 72.76, 61.99, 52.62, 38.97, 38.94, 29.71, 27.41, 27.30, 27.26, 27.02. FAB-MS m/z 931 
(M–1TCA+Na+), 786 (M–2TCA+Na+), C43H45Cl6N5O13 (1052.56). 
2-Azido-3-O-benzyl-4,6-benzylidene-2-deoxy-D-glucopyranosyl-α-(1→4) methyl (n-pentenyl 
2-O-benzoyl-3-O-benzyl-α−L-idopyranosid)-uronate (7). A solution of 63c (59 mg, 
0.284 mmol) and 4-penten-1-ol in CH2Cl2 (2 ml) was cooled to 0°C and 50 µl of a freshly 
prepared TMSOTf- solution (0.03M) added via syringe. The mixture was allowed to warm to r.t. 
during 30 min, diluted with CH2Cl2 (5 ml) and neutralized with sat. NaHCO3 solution (4 ml). 
The separated organic phase was washed with brine, dried over MgSO4 and concentrated in 
vacuo. The residue was eluted from a column of silica gel (4:1→2:1) hexane/ethyl acetate) to 
afford 7 (112 mg, 0.134 mmol, 47%), the corresponding trichloroacetamide (47 mg, 0.051 mmol, 
18%), and the hydrolyzed 1-OH-free compound (76 mg, 0.1 mmol, 35%). Data for 7: TLC (8:1 
toluene/ethyl acetate) Rf 0.62; 1H-NMR (500 MHz, CDCl3) δ 8.17–8.14 (m, 2H; Bz) 7.52–7.13 
(m, 18H, Ph), 5.85–5.73 (m, 1H; CH=CH2), 5.53 (s, 1H; PhCH), 5.22 (bs, 1H; H-1), 5.17 (bs, 
1H; H-2), 5.02–4.95 (m, 3H; CH=CH2, CH2Ph), 4.89 (bs, 1H; H-5), 4.78–4.74 (m, 2H; H-1´), 
4.43–4.35 (m, 2H, CH2Ph, H-6´a), 4.17 (bs, 1H; H-3), 4.12 (bs, 1H; H-4), 4.08–4.00 (m, 1H, H-
6´b), 3.94 (d, J = 10.7 Hz, 1H; CH2Ph), 3.87–3.79 (m, 4H, COOCH3, CH2Ph), 3.68–3.53 (m, 4H, 
CH2Ph, H-3´, H-4´, H-5´), 3.21 (dd, J2´,1´ = 3.5 Hz, J2´,3´ = 9.3 Hz, 1H, H-2´) 2.18–2.11 (m, 2H; 
CH2 (n-Pent.)), 1.77–1.72 (m, 2H; CH2 (n-Pent.)), 1.26 (m, 2H; CH2 (n-Pent.)), 13C-NMR (125 
MHz, CDCl3) δ 170.10, 166.00, 138.40, 138.19, 138.03, 137.91, 133.66, 130.36, 130.06, 129.45, 
129.15, 128.78, 128.71, 128.66, 128.35, 128.34, 128.29, 128.16, 126.53, 126.51, 115.40, 101.82, 
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100.22, 99.63, 82.80, 76.96, 76.42, 75.13, 73.55, 72.66, 68.94, 68.43, 68.00, 67.51, 63.86, 63.54, 
52.68, 30.64, 28.96. Anal. Calcd. for C46H49N3O2 C, 66.10; H, 5.91; N, 5.03; Found C, 66.35; H, 
6.08; N, 5.14.  
2-Azido-3-O-benzyl-2-deoxy-D-glucopyranosyl-α-(1→4)- methyl (n-pentenyl 2-O-benzoyl-3-
O-benzyl-α−L-idopyranosid)-uronate (8). Compound 7 (148 mg, 0.177 mmol) was dissolved 
in CH2Cl2 (3 ml), cooled to 0°C, and EtSH (200 µl, 2.66 mmol) added under stirring. Freshly 
prepared BF3 OEt2-sol. (50 µl, 0.02M) was injected via syringe and the reaction mixture allowed 
to warm up to r.t. After stirring for 3h, TLC- analysis indicated complete consumption of the 
starting material. The acid was neutralized by addition of excess Et3N (500 µl) and the solvents 
removed under reduced pressure. The residue was purified by column chromatography (1:1 
hexane/ethyl acetate) affording 8 (92 mg, 0.13 mmol, 72%) as a colorless oil. 
TLC (2:1 toluene/ethyl acetate) Rf 0.46; 1H-NMR (300 MHz, CDCl3) δ 8.18–8.15 (m, 2H; Bz), 
7.55–7.14 (m, 13H, Ph), 5.86–5.72 (m, 1H; CH=CH2, CH2Ph), 5.21 (bs, 1H; H-1), 5.15 (bs, 1H; 
H-2), 5.01–4.93 (m, 3H; CH=CH2, CH2Ph), 4.88 (d, J5,4 = 1.96 Hz, 1H; H-5), 4.76–4.74 (m, 2H; 
CH2Ph), 4.22 (d, Jgem = 11.0 Hz; 1H, CH2Ph), 4.17–4.08 (m, 3H; H-3, H-4, CH2Ph), 3.86–3.76 
(m, 5H, H-6´a, H-5´, COOCH3), 3.58–3.40 (m, 3H, H-6´b, H-4´, H-3´), 3.10 (dd, J2´,1´ = 3.5 Hz, 
J2´,3´ = 9.6 Hz, 1H; 1H, H-2´), 2.92 (d, JOH,4´ = 3.0 Hz, 1H; OH-4´), 2.31 (bs, 1H; OH-6´), 2.17–
2.10 (m, 2H, CH2 (n-pent.)), 1.75–1.68 (m, 4H; CH2 (n-pent.)), 13C-NMR (75 MHz, CDCl3) δ 
202.76, 179.71, 170.51, 166.03, 138.38, 138.20, 138.00, 133.79, 130.46, 130.10, 129.40, 129.11, 
128.94, 128.78, 128.59, 128.38, 128.31, 128.21, 120.35, 115.40, 99.66, 99.51, 80.31, 75.88, 
75.10, 73.37, 73.00, 72.69, 71.54, 68.44, 68.30, 67.52, 63.57, 62.79, 52.86, 30.61, 28.94. Anal. 
Calcd. for C39H45N3O11 C, 64.01; H, 6.20; N, 5.74; Found C, 64.12; H, 6.18; N, 5.77. 
2-Azido-6-O-benzoyl-3-O-benzyl-2-deoxy-D-glucopyranosyl-α-(1→4) methyl (n-pentenyl 2-
O-benzoyl-3-O-benzyl-α−L-idopyranosid)-uronate (9). Compound 8 (133 mg, 0.178 mmol) in 
CH3CN (3 ml) was cooled to –40°C and treated with 200 µl of a freshly prepared BzCN solution 
(0.9 M, 0.18 mmol) in CH3CN. Upon addition of cat. Et3N (10 µl) stirring was continued at –
40°C for 1.5 h. To drive the reaction to completion, addition of 20 µl of BzCN-sol. (0.9M, 
0.018 mmol) and stirring for 30 min was necessary. The reaction was quenched with MeOH 
(1 ml), the solvents removed under reduced pressure, and the residue subjected to column 
chromatography (8:1 toluene/ethyl acetate) to afford 9 (136 mg, 0.16 mmol, 92%) as a colorless 
oil. 
TLC (4:1 toluene/ethyl acetate) Rf 0.71; 1H-NMR (300 MHz, CDCl3) δ 8.15 (d, J = 7.3 Hz, 2H; 
Bz), 8.00 (d, J = 8.1 Hz, 2H; Bz), 7.99–7.17 (m, 16H; Ph), 5.80–5.73 (m, 1H; CH=CH2), 5.18 
(bs, 1H; H-2), 5.16 (bs, 1H; H-1), 4.99–4.84 (m, 4H; CH=CH2, CH2Ph, H-5, H-6´a), 4.81 (d, 
J1´,2´ = 3.4 Hz, 1H; H-1´), 4.73 (d, Jgem = 11.6 Hz, 1H; CH2Ph), 4.43 (dd, J5´,6´b = 1.9 Hz, J6´a,6´b 
= 12.4 Hz, 1H, H-6´b), 4.31 (d, Jgem = 10.8 Hz, 1H; CH2Ph), 4.06–3.96 (m, 2H; H-3, H-4), 3.81–
3.80 (m, 4H; COOCH3, CH2 (n-pent.)), 3.55–3.42 (m, 3H; H-3´, CH2 (n-pent.), H-4´), 3.12 (dd, 
J2´,1´ = 3.4 Hz, J2´,3´ = 9.9 Hz, 1H; H-2´), 2.92 (d, JOH-4´,4´ = 3.8 Hz, 1H; OH-4´), 2.13 –2.09 (m, 
2H; CH2 (n-pent.)), 1.75–1.66 (m, 2H; CH2 (n-pent.)), 13C-NMR (125 MHz, CDCl3) δ 169.86, 
167.48, 165.61, 137.98, 137.85, 137.66, 133.37, 130.20, 130.05, 129.87, 129.72, 129.49, 128.75, 
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128.65, 128.55, 128.44, 128.36, 128.07, 127.98, 127.89, 127.85, 114.97, 114.83, 99.36, 99.24, 
79.27, 75.67, 74.98, 73.24, 72.33, 71.40, 70.48, 68.07, 67.92, 67.39, 63.22, 63.02, 52.34, 30.21, 
30.06, 28.60. FAB-MS m/z 874 (M+Na+), C46H49N3O12 (835.89). Anal. Calcd. C, 66.10; H, 5.91; 
N, 5.03; Found C, 66.22; H, 6.18; N, 5.12.  
Autocondensation of 9. Compound 9 (66.4 mg, 0.026 mmol) was co-evaporated four times with 
freshly distilled toluene (1.5 ml each) and dried in high vacuum for 2 h. The dried compound 
was then dissolved in CH2Cl2 (1 ml) and stirred for 30 min in the presence of activated molecular 
sieves (3Ǻ). After cooling to 0°C, NIS (19 mg, 0.086 mmol) was added as a solid, followed by 
the slow addition of 50 µl of a freshly prepared Et3SiOTf-sol. (0.044 M, 0.023 mmol). The 
reaction was stirred for 15 min at 0°C then warmed up to r.t. The evolution of the reaction was 
monitored by TLC at intervals of 5 min. After 70 min the reaction was diluted with CH2Cl2 
(5 ml) and quenched by injection of sat. NaHCO3 solution (2 ml). The separated organic phase 
was washed successively with sat. Na2S2O3 solution and brine, dried over MgSO4 and 
concentrated in vacuo. The resulting residue was acetylated with acetic anhydride/pyridine (1:2, 
1 ml) in the presence of a catalytic amount of DMAP for 2h at 0°C. After removal of the solvents 
by extraction with ethyl acetate/water, and co-evaporation with toluene to remove traces of 
pyridine, the crude residue was purified by column chromatography (toluene /ethyl acetate 3:1) 
to furnish a mixture of oligosaccharides which was further separated by preparative TLC 
(toluene /ethyl acetate 5:1) into three fractions (fr. 1, 18.8 mg; fr. 2, 7 mg; fr. 3, 47 mg) and 
analyzed by NMR spectroscopy. The following compounds were isolated. 
Methyl (acetyl O-(4-O-actetyl-2-azido-6-O-benzoyl-3-O-benzyl-2-deoxy-α-D-
gluco-pyranosyl)-(1→4)-O-methyl (2-O-benzoyl-3-O-benzyl-α-L-idopyranosyluronate)-
(1→4)-O-(2-azido-6-O-benzoyl-3-O-benzyl-2-deoxy-α-D-glucopyranosyl)-(1→4)-(2-O-
benzoyl-3-O-benzyl-α-L-idopyranosyl) uronate (10). Compound 10 (9 mg, 0.0054 mmol, 7%) 
was first isolated from the above reaction mixture. 1H-NMR (500 MHz, CDCl3) δ 8.07–7.89 (m, 
8H; ortho Bz), 7.60 –7.00 (m, 32H; Ph), 5.53 (d, J1,2 = 3.2 Hz, 1H; H-1a), 5.34–5.29 (m, 1H; H-
1c), 5.16–5.12 (m, 2H, H-2a, H-4d), 4.98 (d, J3.6 = 3.6 Hz, H-1b), 4.90–4.84 (m, 3H; CH2Ph, H-
1d), 4.75–4.72 (m, 2H, CH2Ph), 4.70–4.63 (m, 4H; H-5c, H-5a, CH2Ph), 4.56 (dd, Jgem = 12 Hz, 
2H¸CH2Ph), 4.49–4.45 (m, 2H; H-6b, H-6d), 4.39 (bs, 1H, H-3a), 4.25 (m, 1H, H-4a), 4.18–3.99 
(m, 5H, H-3c, H-4c, H-6b´, H-5b, H-6d´), 3.91–3.84 (m, 2H, H-5d, H-4b), 3.66 (s, 3H; 
COOCH3), 3.61–3.55 (m, 2H; H-3d, H-3b), 3.46 (s, 3H, COOCH3), 3.33–3.27 (m, 2H; H-2b, H-
2d), 1.94 (s, 3H; COCH3), 1.55 (s, 3H, COCH3). FAB-MS m/z 1694 (M+Na+), C88H85N7O27 
(1672.75). 
4-O-Acetyl-2-azido-6-O-benzoyl-3-O-benzyl-2-deoxy-D-glucopyranosyl-α-(1→4)-O-methyl 
(N-succinimido 2-O-benzoyl-3-O-benzyl-1-deoxy-α−L-idopyranosid)-uronate (11). (8.2 mg, 
0.0094 mmol, 12%). 1H-NMR (500 MHz, CDCl3) δ = 8.02–7.93 (m, 4H; Bz), 7.57–7.28 (m, 
16H, Ph), 6.17 (d, J1,2 = 9.4 Hz, 1H; H-1), 6.13 (t, J2,1 = J2,3 = 8.3 Hz, 1H; H-2), 5.25 (d, J1´,2´ = 
3.6 Hz, 1H; H-1´), 5.16 (t, J4´,3´ = J4´,5´ = 5.75 Hz, 1H; H-4´), 4.87 (d, J5,4 = 5.75 Hz, 1H; H-5), 
4.82 (d, Jgem = 10.7 Hz, 1H, CH2Ph), 4.80 (d, Jgem 10.7 Hz, 1H; CH2Ph), 4.69 (d, Jgem = 11 Hz, 
1H; CH2Ph), 4.63 (d, Jgem 11 Hz, 1H; CH2Ph), 4.46 (dd, J5´,6´a = 2.4 Hz, J6´a,6´b = 12.3 Hz, 1H; H-
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6´a), 4.39–4.31 (m, 2H; H-3, H-4), 4.26 (dd, J6´b,5’ = 5.1 Hz, J6´a,6´b = 12.3 Hz, 1H; H-6´b), 4.17–
4.14 (m, 1H, H-5), 3.86 (t, J3´,2´ = J3´,4´ = 10.0 Hz, 1H; H-3), 3.82 (s, 3H, COOCH3), 3.41 (dd, 
J2´,1´ = 3.6 Hz, J2´,3´ = 10.3 Hz, 1H; H-2´), 2.68–2.53 (m, 4H, CH2 (succ.)), 1.97 (s, 3H; CH3(Ac). 
FAB-MS m/z 930 (M+Na+), C47H46N4O15 (906.89). 
Methyl (N-succinimido-O-(4-O-actetyl-2-azido-6-O-benzoyl-3-O-benzyl-2-deoxy-α-D-gluco-
pyranosyl)-(1→4)-O-methyl (2-O-benzoyl-3-O-benzyl-α-L-idopyranosyluronate)-(1→4)-O-
(2-azido-6-O-benzoyl-3-O-benzyl-2-deoxy-α-D-glucopyranosyl)-(1→4)-(2-O-benzoyl-3-O-
benzyl-1-desoxy-α-L-idopyranosyl) uronate (12). (6.3 mg, 0.0039 mmol, 5%). 1H-NMR (500 
MHz, CDCl3) δ = 8.09–7.91 (m, 8H; Bz, 7.55–7.11(m, 32H; Ph), 6.19 (d, J1a,2a = 9.4 Hz, 1H; H-
1a), 6.07 (t, J2a,1a = J2a,3a = 8.6 Hz, 1H; H-2a), 5.55 (d, J1c,2c = 4.3 Hz, 1H; H-1c), 5.17 (d, J1b,2b 
= 3.4 Hz, 1H; H-1b), 5.16 (t, J4d,5d = J4d,3d = 9.8 Hz, 1H; H-4d), 4.94 (d, Jgem = 10.6 Hz, 1H; 
CH2Ph), 4.92 (d, Jd1,d2 = 3.6 Hz, 1H; H-1d), 4.85–4.72 (m, 8H; CH2Ph, H-5c, H-5a), 4.66 (d, 
Jgem = 10.9 Hz, 1H; CH2Ph), 4.56 (bd, J6a,6a´ = 11.7 Hz, 1H; H-6a), 4.48–4.45 (m, 2H; H-6´d, H-
6b), 4.33–4.26 (m, 2H; H-3a, H-4a), 4.20–4.13 (m, 3H; H-3c, H-5b, H-6´b), 4.07 (t, J4,3 = 4.8 
Hz, 1H; H-4c), 4.03–4.02 (m, 2H, H-5d, H-4b), 3.78–3.74 (m, 1H; H-3b), 3.71 (s, 3H, a-
COOMe), 3.59 (t, J3,2 = J3,4 = 9.6 Hz, 1H; H-3d), 3.46 (s, 3H, c-COOMe), 3.35 (dd, J2,1 = 3.4 
Hz, J2,3 = 9.9 Hz, 1H; H-2b), 3.32 (dd, J2,1 = 3.6 Hz, J2,3 = 10.2 Hz, 1H; H-2d), 2.67–2.51 (m, 
4H, CH2 (succinimide), 1.95 (s, 3H, CH3(Ac). FAB-MS m/z 1654 (M+Na+), C86H84N6O27 
(1633.61). 
 
Autocondensation of 9 (second trial) 
Compound 9 (22.3 mg, 0.026 mmol) was co-evaporated twice with freshly distilled toluene and 
dried in high vacuum for 3h. The dried compound was then dissolved in CH2Cl2 (1 ml) and 
stirred for 30 min in the presence of activated molecular sieves (3Ǻ). After cooling to 0°C, NIS 
(6.4 mg, 0.03 mmol) was added as a solid, followed by the slow addition of 50 µl of a freshly 
prepared TMSOTf-sol. (0.028 M, 0.008 mmol). The progress of the reaction was monitored by 
tlc at intervals of 5 min. After 40 min, additional TMSOTf-sol. (15µl) was added. After 80 min 
the cooling bath was removed. After 2h of stirring no further change in the reaction mixture was 
detected; the mixture was diluted with CH2Cl2 (5 ml) and quenched by injection of sat. NaHCO3 
solution (2 ml). The separated organic phase was washed successively with sat. Na2S2O3 and 
brine, dried over MgSO4 and concentrated in vacuo. The resulting residue was split into two 
fractions by size-exclusion chromatography (Sephadex LH-20, 1:1 MeOH/CH2Cl2). The 
fractions containing faster running products were collected, concentrated in vacuo and acetylated 
with Ac2O/pyridine 2:1 at 0°C for 2 h. 
Chemical shift values for the CH3- groups of Me-esters in the L-IdoA-residues of the proposed 
hexasaccharide (5 mg, calculated average molecular weight: 1748.61 for tetra-/hexasaccharide 
ratio 3:1, 0.0029 mmol) and disaccharide mixture: 1H-NMR (500 MHz, CDCl3): δ 3.84 (s, 3H; 
COOCH3 disaccharide), 3.81 (s, 3H; COOCH3), 3.66 (s, 3H; COOCH3), 3.47 (s, 3H; COOCH3) 
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